Since several trials are currently ongoing to develop a pharmacological treatment for SCA1,19–21, screening for AD SCA using serum NfL could help to initiate disease-modifying treatment earlier and improve long-term outcomes. The gene discussed is NEFL; the disease is Alzheimer disease.